Whole-person Assessment of Response and Risk after transformative therapies: Investigating Outcomes and Resilience in Sickle Cell Disease (WARRIOR-SCD)
Forecast Overview
- NAICS
- 541715
- Incumbent
- Medical College of Wisconsin
- Performance end
- 4/2028
The National Heart, Lung, and Blood Institute (NHLBI) requires contractor support to continue building a cohort of individuals with sickle cell disease (SCD) who have received gene therapy (GT) or hematopoietic cell transplantation (HCT) and to sustain long-term follow-up (LTFU) activities for enrolled participants. While both therapies are available, it has not been established which is safer, more durable, or most effective, nor have rigorous comparisons to untreated persons with SCD who have chosen not to undergo one of these treatments undertaken.
Source
- Source
- HHS SBCX Forecast Export
- Source file
- Forecast.csv
- Official source
- Agency forecast source
- Last verified
- 2026-08-31
Related Federal Entities
- Department of Health and Human Services
- CureSCi Long-Term Follow-Up Consortium: Coordinating Center Activities, Natural History Data Resource (NHDR), and Related Support
- nuMoM2b Heart Health Study 3
- Food Safety Preventive Controls Alliance
- Contract-Animal Food-Florida-Agriculture
- Contract-Human Food-Minnesota-Agriculture HFP Priority #261
- Federal Technology Spending Map
- Federal Opportunity Research